Your shopping cart is currently empty

PRX-08066 Maleic acid is the salt form of PRX-08066.PRX-08066 is a 5-HT receptor 2B antagonist with an IC50 of 3.4 nM that induces selective vasodilation of the pulmonary artery.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $76 | - | In Stock | |
| 5 mg | $180 | - | In Stock | |
| 10 mg | $245 | - | In Stock | |
| 25 mg | $442 | - | In Stock | |
| 50 mg | $652 | - | In Stock | |
| 100 mg | $928 | - | In Stock | |
| 200 mg | $1,260 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $423 | - | In Stock |
| Description | PRX-08066 Maleic acid is the salt form of PRX-08066.PRX-08066 is a 5-HT receptor 2B antagonist with an IC50 of 3.4 nM that induces selective vasodilation of the pulmonary artery. |
| Targets&IC50 | 5-HT2B:3.4 nM |
| In vitro | PRX-08066 inhibits 5-HT-induced mitogen-activated protein kinase activation with IC50 of 12 nM and markedly reduces thymidine incorporation with IC50 of 3 nM in Chinese hamster ovary cells expressing the human 5-HT2BR, which suggests that PRX-08066 can potentially inhibit the pathologic 5-HT-induced vascular muscularization associated with PAH. [1] PRX-08066 inhibits cell proliferation with IC50 of 0.46 nM and with a maximum inhibition of 20% and 5-HT secretion with IC50 of 6.9 nM with a maximum inhibition of 30% in the 5-HT(2B) expressing SI-NET cell line, KRJ-I. PRX-08066 inhibits isoproterenol-stimulated 5-HT release with IC50 of 1.25 nM and a maximum inhibition of 60% in NCI-H720 cells. PRX-08066 (0.5 nM) significantly inhibits ERK phosphorylation in KRJ-I cells. PRX-08066 inhibits TGFβ1, CTGF and FGF2 transcription and secretion in KRJ-I cells. PRX-08066 decreases level of transcripts for Ki67 (84%) as well as Ki67 protein (36.8%) associated with an increase in caspase 3 transcript levels in KRJ-I cells. PRX-08066 decreases level of transcripts of TGFβ1, FGF2 and TPH1 in KRJ-I cells. PRX-08066 significantly increases the number of dead cells (34%) compared with untreated controls in KRJ-I cells. PRX-08066 causes a significant increase in dead/caspase 3 positive cells (76%) and caspase 3 activity (52%) in HEK293 cells. [2] |
| In vivo | In a monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) rat model, PRX-08066 Maleic acid was orally administered at 50 or 100 mg/kg twice daily for 5 weeks. Hemodynamic measurements, MRI, and histological analyses were used to assess treatment effects. PRX-08066 Maleic acid significantly reduced pulmonary arterial pressure, improved right ventricular function, and attenuated right ventricular hypertrophy and pulmonary artery remodeling. [1] |
| Cell Research | 5×103 cells/mL, seeds in 96-well plates at 100 μL (4 plates/experimental condition) are stimulated with PRX-08066 (0.1 μM to 100 nM: n = 6 wells/concentration). After 24 hours, mitochondrial activity is measured after adding MTT (3-[4,5-dimethylthiazol-2-ly]-2.5-diphenyltetrazolium bromide: 0.5 mg/mL per well) for 3 hours. The optical density is read photospectrometrically at 595 nm using a microplate reader. 29 Results are normalized to control (unstimulated cells) and the effective half-maximal concentrations calculated.(Only for Reference) |
| Synonyms | PRX08066 Maleic acid, PRX-08066 maleate |
| Molecular Weight | 517.96 |
| Formula | C23H21ClFN5O4S |
| Cas No. | 866206-55-5 |
| Smiles | C(=C\C(O)=O)\C(O)=O.N(C1=C2C(SC(Cl)=C2)=NC=N1)C3CCN(CC4=CC(C#N)=C(F)C=C4)CC3 |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 91 mg/mL (175.69 mM), Sonication is recommended. H2O: 95 mg/mL (183.41 mM), Sonication is recommended. DMSO: 96 mg/mL (185.34 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.